Rehablist Forums

About lyndellsampsonm

A replay of the conference call will be available commencing approximately one hour after the call. Par has scheduled a conference call for at 9:00 am EST to discuss generic fluticasone results for the fourth quarter and full year 2008. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any hair removal medication applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements. This is compared with reported revenues of $155.1 million and income from continuing operations of $5.5 million, or $0.16 per diluted share, for the same period in 2007. The online pharmacies vicodin $15.4 million fourth quarter charge related rozerem dosing to the restructuring will result in cash expenditures of approximately $6.0 million in 2009. Par Pharmaceutical Reports Fourth Quarter and Full Year 2008 Results WOODCLIFF LAKE, N.J., / - / -- Par Pharmaceutical Companies, Inc. Risk factors that might affect such forward-looking statements include generic fluticasone those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended , in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions.

To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. This is compared with reported net income of $4.3 million, or $0.12 per share, for the same period in 2007. Strativa revenues increased 2.7% from the prior year to $87.1 million driven by a mid-year price ciprofloxacin increase, fees related to the co-promotion of Androgel(R), international pharmacy solutions and timing of trade buying patterns offset by a more challenging reimbursement valacyclovir cost environment.

The replay dial-in number is 888-286-8010 for domestic callers and 617-801-6888 for international callers. Fourth quarter 2008 reported, or GAAP, loss from continuing operations also included the write-off of a restructuring charge of $15.4 million and other related costs of $3.8 million, $49.2 million in charges due to an unfavorable court decision and related legal fees, $5.3 million gain on non-core ANDA sales and the generic lexapro sale of other product rights, $4.9 million impairment charge related to various investments, and a $7.9 million gain related to arnold debt extinguishment. Adjusting for these items and the fourth quarter special items, income from continuing operations for the full year ended would have been $1.8 million, or $0.05 per diluted share.

The decrease was due primarily to a net reduction of $11.7 million of one-time Strativa celexa dosage anxiety milestone payments. Adjusting for these items, income from continuing operations for the fourth xalatan eye drops quarter of 2007 would have been $6.5 million, or $0.19 per diluted share. Generic product gross margin decreased to 22.2% of generic revenues in 2008 from 29.8% of generic revenues antibiotic amoxicillin in 2007 driven by increased sales of lower margin metoprolol succinate, lower sales of existing products as mentioned above, and an impairment charge of $4.9 million for nabumetone, and lower inventory write-offs, in addition to the other factors discussed above. tricor

Strativa's gross margin increased to 77.7% of branded revenues from 76.0% in 2007 due to revenue growth discussed above. Revenues for the fourth quarter 2008 increased 4.0% compared with the same period reboxetine reviews in 2007 due primarily to the launch of sumatriptan succinate injection, increased sales of metoprolol and Megace(R) ES. For the year ended , Par reported total revenues of $578.1 million and a loss from continuing operations of $45.9 million, or $1.38 per share. "Given the challenging environment of 2008, we are pleased erectile dysfunction drugs online with the operating results over the last two quarters," stated Eldin G. For the fourth quarter norfloxacin ear / eye drops ended , Par reported total revenues of $161.3 million and a loss from continuing operations of $30.5 million, or $0.91 per share. For the year ended total revenue decreased 24.9% to $578 million compared with the same period a year earlier as a result of a decrease in the number of new product launches, trimming of Par's generic product portfolio, increased competition in Par's generic products.

Research and development (R&D) expenses decreased 23.2% from the year ended , to $59.7 million, and represented ortho tri cyclen generic price 10.3% of total revenues. Safe Harbor Statement Certain statements in this news tricor release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Generic R&D expense decreased $8.0 million due to lower internal development costs, lower performance incentive compensation of $4 million, and the non-recurrence of one-time costs associated with a third party development agreement. PRX) today reported fourth quarter viagra online without prescription canada and full year 2008 results ended. For the full year 2008, Par reported a loss of $47.8 million, or $1.43 per share. Access to the live webcast can be made via Par's website at and will be available for 30 days.

LePore, chairman, president and chief executive officer. This is compared with reported revenues of $769.7 million and income from continuing operations of $51.1 million, or $1.47 per diluted share, for 2007. Par's reported, or GAAP, loss from continuing operations for the year ended , included the write-off of an intangible asset and certain inventories related to the trimming of its generic product portfolio of $5.5 million, a charge related to a government pricing contingency viagra cost of $4.8 million, a $7.8 million net impairment charge related to various investments, $7.5 million in development milestone payments to MonoSol Rx and Alfacell, and $9.0 million of gains from the sale of non-core ANDAs and other product rights. Products which experienced significant volume and pricing declines included fluticasone, propranolol, cabergoline, various amoxicillin products, ranitidine syrup, tramadol HCl and acetaminophen tablets driven by Par's exit from the market, and lower royalty payments of ondansetron tablets, among others.

Revenues from Strativa represented 15.1% of total revenues, as compared to 11.0% in 2007. For a copy of Par's 2008 Annual nexium medication cost Report on Form 10-K, visit Investors/SEC Filings on the Par web site at. Revenues from Par's generic segment declined 28.3% for the full year 2008 to $491.1 million primarily due to competitive pressures that adversely affected the volume and pricing of certain existing products.

Adjusting for these items and other special items, income from continuing operations for the fourth quarter 2008 would have been $7.1 million, or $0.21 per diluted share. SOURCE Par Pharmaceutical Companies, Inc.. The dial-in number is 888-679-8034 for domestic callers and 617-213-4847 for international callers. This is compared with reported net income of $49.9 million, or $1.43 per share in 2007. Par's 2008 gross margin represented best online drug store 30.5% of total revenues, a decrease from 34.9% in 2007. By comparison, and in addition to the fourth quarter 2007 events cited above, reported GAAP income from continuing operations for the full year 2007 included a $20.0 million gain on the sale to Optimer of marketing rights to the investigational drug Difimicin (Par 101), a $4.5 million investment gain on the sale of shares of Optimer com stock, and net settlement gains of $0.6 million. These benefits were tempered by $19.2 million of costs related to business development activities in support of Strativa Pharmaceuticals, Par's branded division, a $6.0 million loss on an investment, $1.6 million of severance costs.

The decrease in SG&A expense was primarily due to lower employee compensation, the non-recurrence of the 2007 stock option tender offer and the resulting lower stock option costs, and lower expenses relates to sales and marketing of Megace(R) ES, which offset higher legal fees, severance costs and increased outside consulting costs. Par invites investors and the general public to listen to a webcast of the conference call. By comparison, fourth quarter 2007 results included a pre-tax gain of $3.1 million from Par's sale of its remaining investment in Optimer Pharmaceutical, Inc. Par anticipates generic propecia cost these actions will generate annualized operating expense savings in a range near $45 million. As of , Par had working capital of $193.8 million, which includes $142 million of current liabilities due to mature in September 2010. Par Pharmaceutical Companies, Inc. Develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets.

"This momentum should continue into 2009 as the results of our restructuring online pharmacies canada takes hold and solid product sales continue." In October, Par announced its plans to resize its generic division by significantly reducing its research and development expense and trimming its product portfolio resulting in a workforce reduction of approximately 190. These

.